Literature DB >> 29512406

Cytokine signaling in multiple sclerosis: Lost in translation.

Kerstin Göbel1, Tobias Ruck1, Sven G Meuth1.   

Abstract

Multiple sclerosis (MS) is a common neurological disorder of putative autoimmune origin. Clinical studies delineate abnormal expression of specific cytokines over the course of disease. Preclinical studies using animal models of MS have yielded promising results in manipulating the activity of certain cytokines to improve the clinical outcome. However, the translation of these findings into the clinic is often disappointing. The reason for this might be the complex nature of cytokine networks and the pathogenesis of neuroinflammation, as well as an oversimplified interpretation of preclinical observations. This review presents an overview on cytokines that potentially contribute to the development of MS and provides examples of success and failure in translating basic science into clinical benefit for people with MS.

Entities:  

Keywords:  Multiple sclerosis; T helper cells; cytokine; experimental autoimmune encephalomyelitis; interleukin

Mesh:

Substances:

Year:  2018        PMID: 29512406     DOI: 10.1177/1352458518763094

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  27 in total

1.  PET Imaging of the P2X7 Ion Channel with a Novel Tracer [18F]JNJ-64413739 in a Rat Model of Neuroinflammation.

Authors:  Tamara Berdyyeva; Chunfang Xia; Natalie Taylor; Yingbo He; Gang Chen; Chaofeng Huang; Wei Zhang; Hartmuth Kolb; Michael Letavic; Anindya Bhattacharya; Anna Katrin Szardenings
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

2.  Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.

Authors:  Chiara Tremolanti; Chiara Cavallini; Laurence Meyer; Christian Klein; Eleonora Da Pozzo; Barbara Costa; Lorenzo Germelli; Sabrina Taliani; Christine Patte-Mensah; Ayikoé-Guy Mensah-Nyagan
Journal:  Mol Neurobiol       Date:  2022-01-11       Impact factor: 5.590

3.  Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles.

Authors:  Dhanu Gupta; Oscar P B Wiklander; André Görgens; Mariana Conceição; Giulia Corso; Xiuming Liang; Yiqi Seow; Sriram Balusu; Ulrika Feldin; Beklem Bostancioglu; Rim Jawad; Doste R Mamand; Yi Xin Fiona Lee; Justin Hean; Imre Mäger; Thomas C Roberts; Manuela Gustafsson; Dara K Mohammad; Helena Sork; Alexandra Backlund; Per Lundin; Antonin de Fougerolles; C I Edvard Smith; Matthew J A Wood; Roosmarijn E Vandenbroucke; Joel Z Nordin; Samir El-Andaloussi
Journal:  Nat Biomed Eng       Date:  2021-10-06       Impact factor: 25.671

4.  Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis.

Authors:  Antonio Bruno; Ettore Dolcetti; Federica Azzolini; Alessandro Moscatelli; Stefano Gambardella; Rosangela Ferese; Francesca Romana Rizzo; Luana Gilio; Ennio Iezzi; Giovanni Galifi; Angela Borrelli; Fabio Buttari; Roberto Furlan; Annamaria Finardi; Francesca De Vito; Alessandra Musella; Livia Guadalupi; Georgia Mandolesi; Diego Centonze; Mario Stampanoni Bassi
Journal:  Genes (Basel)       Date:  2022-05-17       Impact factor: 4.141

5.  Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response.

Authors:  Marina Boziki; Christos Bakirtzis; Styliani-Aggeliki Sintila; Evangelia Kesidou; Evdoxia Gounari; Aliki Ioakimidou; Vasiliki Tsavdaridou; Lemonia Skoura; Asimina Fylaktou; Vasiliki Nikolaidou; Maria Stangou; Ioannis Nikolaidis; Virginia Giantzi; Eleni Karafoulidou; Paschalis Theotokis; Nikolaos Grigoriadis
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

Review 6.  What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?

Authors:  Julia Krämer; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2022-07-06       Impact factor: 6.088

7.  Cardiac Autonomic Dysfunction in Myasthenia Gravis and Relapsing-Remitting Multiple Sclerosis-A Pilot Study.

Authors:  Łukasz Rzepiński; Monika Zawadka-Kunikowska; Julia L Newton; Paweł Zalewski
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

8.  m6A demethylase ALKBH5 controls CD4+ T cell pathogenicity and promotes autoimmunity.

Authors:  Jing Zhou; Xingli Zhang; Jiajia Hu; Rihao Qu; Zhibin Yu; Hao Xu; Huifang Chen; Lichong Yan; Chenbo Ding; Qiang Zou; Youqiong Ye; Zhengting Wang; Richard A Flavell; Hua-Bing Li
Journal:  Sci Adv       Date:  2021-06-16       Impact factor: 14.136

9.  N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition, but Not Fatty Acid Amide Hydrolase Inhibition, Prevents the Development of Experimental Autoimmune Encephalomyelitis in Mice.

Authors:  Pauline Bottemanne; Owein Guillemot-Legris; Adrien Paquot; Julien Masquelier; Michael Malamas; Alexandros Makriyannis; Mireille Alhouayek; Giulio G Muccioli
Journal:  Neurotherapeutics       Date:  2021-07-07       Impact factor: 6.088

10.  Inflammation and Corticospinal Functioning in Multiple Sclerosis: A TMS Perspective.

Authors:  Mario Stampanoni Bassi; Fabio Buttari; Luana Gilio; Nicla De Paolis; Diego Fresegna; Diego Centonze; Ennio Iezzi
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.